Management Protocol for Unresectable Wilms Tumor
For unresectable Wilms tumor, initiate neoadjuvant chemotherapy with Revised Regimen UH-2 (for diffuse anaplasia) or Regimen VAD (for favorable histology), re-image at 6 weeks to assess resectability, and proceed to nephrectomy with regional lymph node sampling when feasible, followed by adjuvant chemotherapy and radiation therapy based on histology and stage. 1
Initial Assessment and Biopsy Decision
- Biopsy is strongly recommended for unilateral unresectable tumors without predisposing conditions to determine histology before starting therapy 1
- Avoid upfront biopsy in bilateral tumors or unilateral tumors with known predisposing conditions (Beckwith-Wiedemann, WAGR, Denys-Drash syndromes) 1
- Any anaplasia found on biopsy is automatically classified as diffuse anaplasia 1
Treatment Algorithm by Histology
For Diffuse Anaplastic Wilms Tumor (Unresectable)
Neoadjuvant Phase:
If Resectable at Week 6:
- Perform nephrectomy with regional lymph node sampling 1
- Continue Revised Regimen UH-2 postoperatively 1
- Initiate radiation therapy within 10-14 days after surgery 1
If Still Unresectable at Week 6:
Radiation Therapy Specifications:
- Flank radiation for local stage II disease 1
- Flank OR whole abdomen for local stage III disease 1
- For stage III diffuse anaplasia: 19.8 Gy to flank + 10.5 Gy whole abdomen followed by 9 Gy to flank (reduces local relapse from 14.8% to 6.4%) 1
- Whole lung irradiation if lung metastases present 1
- Radiation to other metastatic sites as indicated 1
For Favorable Histology Wilms Tumor (Unresectable)
Neoadjuvant Phase:
Response-Based Management at Week 6:
Complete Response (CR) of renal tumors:
- Switch to Regimen DD4A 1
- No flank radiation needed 1
- Whole lung irradiation for lung metastases if present 1
Partial Response - Now Resectable:
- Perform partial nephrectomy (one or both sides) with regional lymph node sampling 1
- Adjust chemotherapy based on pathology:
Partial Response - Still Unresectable:
- Continue VAD for another 6 weeks 1
- Re-image at week 12 1
- Surgery should not be delayed beyond 12 weeks as continued chemotherapy rarely yields further shrinkage 1
Less than Partial Response or Progression at Week 6:
- Perform bilateral open biopsies if partial nephrectomy not feasible 1
- Adjust chemotherapy based on histology:
- Re-evaluate at week 12 1
Critical Surgical Principles
- Nephron-sparing surgery is preferred when feasible to preserve kidney function 1
- Options include: partial nephrectomy (one or both sides) OR total nephrectomy on one side with partial nephrectomy contralateral 1
- Regional lymph node sampling is mandatory in all cases 1
- Surgery should be performed in a high-volume center with pediatric oncology expertise 2
Radiation Therapy Planning Considerations
Critical Pitfall to Avoid:
- Plan for both abdominal and lung fields simultaneously during initial RT planning, even if lung RT may not ultimately be needed 1
- This minimizes overlapping fields between abdomen and lung treatments given at different times 1
- Some field overlap is expected and necessary to adequately cover targets 1
Evidence Quality Notes
The recommendations are based on the 2025 NCCN Guidelines 1, which incorporate data from the AREN0321 trial showing improved outcomes with revised UH-2 regimen for diffuse anaplasia (4-year OS 73.7% vs 59.2% in prior studies) 1. The distinction between upfront surgery (COG/NWTSG approach) versus neoadjuvant chemotherapy (SIOP approach) has been resolved in favor of neoadjuvant therapy for unresectable tumors, as continuing chemotherapy beyond 12 weeks provides minimal additional benefit 1.
Key Point: Local stage III designation refers to the primary tumor staging regardless of metastatic disease presence, and this determines flank/abdominal radiation decisions 1.